ABSTRACT
An initial bone mineral density (BMD) measurement is used to diagnose osteoporosis and decide whether patients need treatment, but the utility of repeating this test in those on treatment or on a drug holiday (ie, during a pause in bisphosphonate treatment) is controversial. Here, we present evidence for and against the use of BMD monitoring in patients receiving antiresorptive therapy or on a drug holiday, and give our recommendations, arguing against a one-size-fits-all approach.
- Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.
- Tayyab S. Khan, MD
- Partha Sinha, MD, PhD
- Harold Rosen, MD⇑
- Department of Medicine, Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA
- Address:
Harold Rosen, MD, Department of Medicine, Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, GZ-609, 330 Brookline Avenue, Boston, MA 02215; hrosen{at}bidmc.harvard.edu
ABSTRACT
An initial bone mineral density (BMD) measurement is used to diagnose osteoporosis and decide whether patients need treatment, but the utility of repeating this test in those on treatment or on a drug holiday (ie, during a pause in bisphosphonate treatment) is controversial. Here, we present evidence for and against the use of BMD monitoring in patients receiving antiresorptive therapy or on a drug holiday, and give our recommendations, arguing against a one-size-fits-all approach.
- Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.